Jevtana (cabazitaxel) Injection Now Available in the U.S. - Jevtana plus prednisone is the first and only therapy approved for patients with metastatic hormone-refractory prostate cancer previously treated with docetaxel

(cabazitaxel) Injection Now

Available in the U.S.

- Jevtana plus prednisone is the first and only therapy approved for patients

with metastatic hormone-refractory prostate cancer previously treated

with docetaxel-based therapy -

Paris, France July 19, 2010 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that

Jevtana (cabazitaxel) Injection is now available in the United States for patients with metastatic

hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-based treatment regimen. The availability of Jevtana comes just one month following a priority review and approval by the U.S. Food and Drug Administration (FDA).

The prostate cancer community is thrilled to now have a new treatment option available for these patients whose disease is very

difficult to treat, said Oliver Sartor, M.D., Piltz Professor for Cancer Research at Tulane Medical School, New Orleans, and North American principal investigator for the pivotal TROPIC trial. Jevtana will help fill a critical

treatment gap, since it is the first treatment approved for patients with this stage of metastatic hormone-refractory prostate cancer.

Jevtana in combination with prednisone was approved based on results from the Phase 3 TROPIC clinical study involving 755 patients with mHRPC previously

treated with a docetaxel-containing treatment regimen. Results from this trial demonstrated a statistically significant 30% [HR=0.70 (95% CI: 0.59-0.83); P<0.0001] relative reduction in the risk of death in mHRPC among patients taking Jevtana in

combination with prednisone compared with an active chemotherapy regimen consisting of a standard dose of mitoxantrone and prednisone. Median overall survival in the patients receiving Jevtana plus prednisone was 15.1 (14.1 16.3) months

compared to 12.7 (11.6 13.7) months for patients receiving mitoxantrone plus prednisone.

For many years, treatment of

advanced hormone refractory prostate cancer after docetaxel-containing therapy has remained an unmet medical need. The ability to introduce Jevtana for this patient population is an important achievement for sanofi-aventis Oncology that exemplifies

our deep commitment to bringing innovative new therapies to the cancer community, said Debasish Roychowdhury, M.D., Senior Vice President, Global Oncology, sanofi-aventis.

For patients with metastatic prostate cancer, hormone therapy is frequently the first treatment offered. Patients who no longer respond to hormone

therapy often receive chemotherapy. However, some patients develop chemotherapy resistance, and their disease continues to progress. Before Jevtana, no available second-line treatment options were proven to provide a survival benefit in mHRPC

patients. The combination of Jevtana and prednisone is the first and only therapy to have shown a significant survival benefit for patients with mHRPC previously treated with a docetaxel-containing regimen in this setting.

In the TROPIC Study, the most common ( 10%) grade 1-4

adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough,

arthralgia, and alopecia. The most common ( 5%) grade 3-4 adverse reactions in patients who received Jevtana were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.

Treatment discontinuations due to adverse drug reactions occurred in 18% of patients who received Jevtana and 8% of patients who received mitoxantrone. The most common adverse reactions leading to treatment discontinuation in the Jevtana group were

neutropenia and renal failure. Deaths due to causes other than disease progression within 30 days of last study drug dose were reported in 18 (5%) Jevtana patients and three (less than 1%) mitoxantrone-treated patients. The most common fatal

adverse reactions in Jevtana patients were infections (n=5) and renal failure (n=4). One death was due to diarrhea-induced dehydration and electrolyte imbalance.

Jevtana (cabazitaxel) Injection

Jevtana, a microtubule inhibitor, is approved in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate

cancer (mHRPC) previously treated with a docetaxel-based treatment regimen. Jevtana is to be administered intravenously. Jevtana was granted fast track designation by the FDA in November 2009. The rolling new drug application (NDA) submission was

completed in March 2010 and was granted priority review in April 2010; Jevtana was approved by the FDA less than three months later. A registration dossier of Jevtana is also under regulatory review by other regulatory authorities, including the

European Medicines Agency.

Important Safety Information for Jevtana

WARNINGS AND PRECAUTIONS

Please see full prescribing

information for Jevtana, including boxed WARNING, at http://products.sanofi-aventis.us/jevtana/jevtana.pdf

Incidence of Prostate Cancer

Worldwide, prostate cancer ranks third in cancer incidence and sixth in cancer mortality

in men. In the U.S., prostate cancer remains the second most common cause of cancer death among men after lung cancer. In 2009, an estimated 192,000 new cases were anticipated in the U.S., while 27,000 men were expected to have died from the

disease. For many patients with prostate cancer, their disease continues to progress despite prior treatment including surgical and/or hormonal castration followed by chemotherapy. Metastatic prostate cancer indicates that the cancer has

spread to the lymph nodes or other parts of the body, particularly the bones. Castration resistant/hormone-refractory prostate cancer means that the cancer has continued to grow despite the suppression of male hormones that fuel the growth of

prostate cancer cells. An estimated 10-20% of patients with prostate cancer are diagnosed when the cancer has already metastasized.

sanofi-aventis Oncology

Formed in March 2010, sanofi-aventis Oncology is targeting cancer on all fronts in an effort to address unmet

medical needs for a broad range of patients. Starting with a deep understanding of the mechanisms by which cancer develops, grows and spreads as well as identifying the right science early in the discovery process, the company employs innovative

approaches to bring the right medicines to the right patients.

There are currently more than 10 compounds in development across a broad

scientific platform, including cytotoxic, antimitotic, anti-angiogenic agents, antivascular agents, monoclonal antibodies and cancer vaccines, as well as supportive care therapies. Four of these compounds are now being investigated in phase 3

clinical studies aimed at multiple solid and hematologic tumors.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.

Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking

statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial

results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects, anticipates,

believes, intends, estimates, plans and similar expressions. Although sanofi-aventis management believes that the expectations reflected in such forward-looking statements are reasonable,

investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and

developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development,

future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product

candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be

commercially successful, the future approval and commercial success of therapeutic alternatives, the Group s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and

the AMF made by sanofi-aventis, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in sanofi-aventis annual report on Form 20-F for the year ended December 31,

2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Mobile: +33 (0) 6 08 18 94 78

E-mail: marisol.peron@sanofi-aventis.com

Tel: 1 - (908) 981-6573

E-mail: emmy.tsui@sanofi-aventis.com